The majority of radiobiology studies follow a classic linear research pathway — from laboratory-based research to preclinical studies that can lead to clinical trials. Researchers at Queen’s University Belfast are beginning to challenge this approach by reverse translating knowledge gained in the clinic back into the laboratory. Recent work has demonstrated the power of this approach in being able to accurately model clinical observations of radiation induced cardiac toxicity. Queen’s University Belfast also been able to successfully reverse translate an injectable liquid fiducial marker (BioXmark, Nanovi A/S) from the clinic to refine preclinical radiotherapy protocols.
In this webcast recording, Xstrahl hosts Dr. Karl Butterworth as he describes his team’s research using SARRP for reverse translation and how clinical data can directly inform new discoveries in the laboratory. Learn how clinical trials normally viewed as the endpoint for establishing novel therapeutic approaches may offer opportunities for new areas of preclinical research.
